



Goodwin Biotechnology Announces the Return of Two Important Monoclonal Antibody Projects from Alethia Biotherapeutics

October, 2013

Plantation, Florida and Montreal, Quebec -- Goodwin Biotechnology, Inc. announced that Alethia Biotherapeutics Inc., a privately held biotechnology company focusing on the development of therapeutic monoclonal antibodies, has contracted for the next phase of manufacturing activities for two of their leading drug candidates:

- AB-16B5, a monoclonal antibody which targets secreted clusterin for the inhibition of cancer-associated epithelial-to-mesenchymal transition (EMT), a mechanism that is one of the most important contributors to tumor invasion and metastasis.
- AB-25E9, a first-in-class bone antiresorptive monoclonal antibody with a novel mechanism of action that is being developed for the treatment of bone loss in oncology indications such as multiple myeloma and invasive carcinomas.

“We feel that being selected by Alethia Biotherapeutics as a partner to continue the development of two of their leading drug candidates is a vote of confidence in our commitment and dedication to cGMP manufacturing of high quality products on time and on budget,” said SooYoung Lee, PhD, Chief Operating Officer at Goodwin Biotechnology. “We take great pride in contributing to important advances in medicine, as exemplified by these two products.”

“Entrusting our two lead product candidates to a contract manufacturer is not something we take lightly. We selected Goodwin Biotechnology based on the quality of work they had done for us in the past on both projects,” notes Mario Filion, PhD, Executive Vice President and Chief Scientific Officer at Alethia Biotherapeutics. “We are committed to improving treatments available to patients with cancer and other significant diseases. By accelerating these innovative biological therapeutics through the development phase and into clinical trials, we move closer to making a significant impact on the lives of patients and their families.”

About Goodwin Biotechnology, Inc.

Goodwin Biotechnology is a world-class CMO that offers a Single Source Solution™ through partnerships with clients for cell line development or exploratory proof of concept projects through process development and cGMP contract manufacturing of monoclonal antibodies, recombinant proteins, vaccines and Antibody Drug Conjugates (ADCs) for early and late stage clinical trials. By

working with Goodwin Biotechnology, our clients can enhance the value of their product candidates with clear development and manufacturing strategies as well as a road map to meet the highest quality product requirements from the milligram and gram range to kilogram quantities as the product candidates move along the clinical approval pathway in a cost-effective, timely, and cGMP compliant manner to enhance patients' lives. With over 20 years of experience as an independent contract manufacturer, Goodwin Biotechnology has worked as a strategic partner with companies of all sizes from small university spin-offs to major research institutes, government agencies and large, established and multi-national biopharmaceutical companies. Additional information may be found at www.GoodwinBio.com.

About Alethia Biotherapeutics Inc.

Alethia is a privately held biotechnology company based in Montreal. Alethia develops monoclonal antibody therapeutics against novel clinically relevant targets identified using its patented STAR discovery technology. Alethia is well funded with top-tier investors committed to the success of the Company notably, Agechem Venture Fund, BDC Capital and GO Capital.

For more information, please contact:

Goodwin Biotechnology	Alethia Biotherapeutics	
Robin McCallum Business Development Manager (954) 327-9656 RMcCallum@GoodwinBio.com	Yves Cornellier President and CEO 514-858-7666 ext. 206 ycornellier@ alethiabio.com	Mario Filion, Ph.D. Executive VP, CSO 514-858-7666 ext. 207 mariof@alethiabio.com